Eva Klein
#14,443
Most Influential Person Now
Hungarian-Swedish biologist
Eva Klein's AcademicInfluence.com Rankings
Eva Kleinbiology Degrees
Biology
#398
World Rank
#712
Historical Rank
Biotechnology
#16
World Rank
#16
Historical Rank
Molecular Biology
#214
World Rank
#218
Historical Rank
Download Badge
Biology
Why Is Eva Klein Influential?
(Suggest an Edit or Addition)According to Wikipedia, Eva Klein is a Hungarian-Swedish scientist. Klein has worked at the Karolinska Institute since leaving Hungary in 1947. She is regarded as a founder of cancer immunology. Her life and career choices as a young Jewish woman were constrained by discrimination, and she survived the late stages of German occupation in hiding. A medical doctor with a PhD in biology, she has worked in cancer immunology and virology.
Eva Klein's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- „Natural”︁ killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype (1975) (1747)
- „Natural”︁ killer cells in the mouse. II. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Characteristics of the killer cell (1975) (1068)
- Surface IgM-kappa specificity on a Burkitt lymphoma cell in vivo and in derived culture lines. (1968) (812)
- Demonstration of resistance against methylcholanthrene-induced sarcomas in the primary autochthonous host. (1960) (806)
- Evolution of tumours and the impact of molecular oncology (1985) (676)
- A MICROASSAY FOR CELL-MEDIATED IMMUNITY (1970) (470)
- Classification of current anticancer immunotherapies (2014) (357)
- Establishment in continuous culture of a new type of lymphocyte from a “burkitt‐like” malignant lymphoma (line d.g.‐75) (1977) (299)
- ANTIGENIC PROPERTIES OF LYMPHOMAS INDUCED BY THE MOLONEY AGENT. (1964) (293)
- Properties of the K562 cell line, derived from a patient with chronic myeloid leukemia (1976) (290)
- Search for tumor-specific immune reactions in Burkitt lymphoma patients by the membrane immunofluorescence reaction. (1966) (288)
- A subpopulation of normal B cells latently infected with Epstein-Barr virus resembles Burkitt lymphoma cells in expressing EBNA-1 but not EBNA-2 or LMP1 (1995) (204)
- Burkitt lymphoma. (2005) (203)
- Conditioned tumorigenicity of activated oncogenes. (1986) (171)
- Epstein–Barr virus infection in humans: from harmless to life endangering virus–lymphocyte interactions (2007) (168)
- Immune surveillance against virus-induced tumors and nonrejectability of spontaneous tumors: contrasting consequences of host versus tumor evolution. (1977) (168)
- RELATION BETWEEN EPSTEIN-BARR VIRAL AND CELL MEMBRANE IMMUNOFLUORESCENCE OF BURKITT TUMOR CELLS (1968) (160)
- IMMUNOGLOBULIN AND GLUCOSE-6-PHOSPHATE DEHYDROGENASE AS MARKERS OF CELLULAR ORIGIN IN BURKITT LYMPHOMA (1973) (157)
- Membrane immunofluorescence reactions of Burkitt lymphoma cells from biopsy specimens and tissue cultures. (1967) (156)
- Down-regulation of class I HLA antigens and of the Epstein-Barr virus-encoded latent membrane protein in Burkitt lymphoma lines. (1987) (146)
- Characteristics of new cell lines derived from Burkitt lymphomas (1969) (145)
- Studies on cytotoxicity generated in human mixed lymphocyte cultures. II. Anti-K562 effectors are distinct from allospecific CTL and can be generated from NK-depleted T cells. (1978) (141)
- Growth and antigenic properties of a biopsy‐derived Burkitt's lymphoma in thymus‐less (nude) mice (1973) (131)
- Exosomes Containing Glycoprotein 350 Released by EBV-Transformed B Cells Selectively Target B Cells through CD21 and Block EBV Infection In Vitro (2011) (130)
- TUMOR INFILTRATING LYMPHOCYTES * (1976) (123)
- Human tumour—lymphocyte interaction in vitro. V. Comparison of the reactivity of tumour‐infiltrating, blood and lymph‐node lymphocytes with autologous tumour cells (1977) (122)
- Natural cytotoxicity in man: activity of lymph node and tumor‐infiltrating lymphocytes (1977) (118)
- Oncogene activation and tumor progression. (1984) (116)
- Large-scale hypomethylated blocks associated with Epstein-Barr virus–induced B-cell immortalization (2014) (116)
- Myc/Ig juxtaposition by chromosomal translocations: some new insights, puzzles and paradoxes. (1985) (114)
- THE LYMPHOCYTE RESPONSE TO PRIMARY MOLONEY SARCOMA VIRUS TUMORS IN BALB/c MICE (1973) (113)
- Lymphocyte cytotoxicity against autologous tumour biopsy cells in humans (1977) (112)
- Exosomes Derived from Burkitt’s Lymphoma Cell Lines Induce Proliferation, Differentiation, and Class-Switch Recombination in B Cells (2014) (111)
- Variation of antigenic characteristics between different mouse lymphomas induced by the Moloney virus. (1966) (108)
- The function of human NK cells is enhanced by β‐glucan, a ligand of CR3 (CD11b/CD18) (1991) (108)
- Selection of an immunoresistant Moloney lymphoma subline with decreased concentration of tumor-specific surface antigens. (1968) (106)
- Disappearance of the NK effect after explantation of lymphocytes and generation of similar nonspecific cytotoxicity correlated to the level of blastogenesis in activated cultures. (1980) (106)
- Effect of frequently used chemotherapeutic drugs on the cytotoxic activity of human natural killer cells (2007) (105)
- Interaction of Epstein-Barr virus (EBV) with human B-lymphocytes. (2010) (101)
- The neutral cysteine protease bleomycin hydrolase is essential for epidermal integrity and bleomycin resistance. (1999) (98)
- CONVERSION OF SOLID NEOPLASMS INTO ASCITES TUMORS (1955) (98)
- Differentiation-dependent sensitivity of human B-cell-derived lines to major histocompatibility complex-restricted T-cell cytotoxicity. (1986) (97)
- Cytotoxic and neutralization tests with serum and lymph node cells of isologous mice with induced resistance against gross lymphomas. (1962) (96)
- Role of alloantigens in natural killing. Allogeneic but not autologous tumor biopsy cells are sensitive for interferon-induced cytotoxicity of human blood lymphcoytes (1980) (96)
- Decreased “natural killer” effect in tumor‐bearing mice and its relation to the immunity against oncorna virus‐determined cell surface antigens (1976) (96)
- Large granular lymphocytes inhibit the in vitro growth of autologous Epstein-Barr virus-infected B cells. (1983) (96)
- Demonstration of host resistance against isotransplantation of lymphomas induced by the Gross agent. (1962) (96)
- IN VITRO CYTOTOXICITY BY A NONTHYMUS-PROCESSED LYMPHOCYTE POPULATION WITH SPECIFICITY FOR A VIRALLY DETERMINED TUMOR CELL SURFACE ANTIGEN (1972) (95)
- Increased sensitivity of human lymphoid lines to natural killer cells after induction of the Epstein-Barr viral cycle by superinfection or sodium butyrate (1980) (95)
- IL-10 can induce the expression of EBV-encoded latent membrane protein-1 (LMP-1) in the absence of EBNA-2 in B lymphocytes and in Burkitt lymphoma- and NK lymphoma-derived cell lines. (2006) (92)
- Humoral and cellular factors in homograft and isograft immunity against sarcoma cells. (1960) (92)
- TUMOR‐SPECIFIC TRANSPLANTATION ANTIGENS * (1969) (90)
- Characterization of ebv‐carrying b‐cell populations in healthy seropositive individuals with regard to density, release of transforming virus and spontaneous outgrowth (1987) (89)
- Specificity of auto‐tumor cytotoxicity exerted by fresh, activated and propagated human t lymphocytes (1982) (83)
- Lysis of tumor biopsy cells by autologous T lymphocytes activated in mixed cultures and propagated with T cell growth factor (1982) (82)
- Identification of wild‐type and mutant p53 peptides binding to HLA‐A2 assessed by a peptide loading‐deficient cell line assay and a novel major histocompatibility complex class I peptide binding assay (1994) (82)
- SYNERGISTIC OR ANTAGONISTIC EFFECT OF DIFFERENT ANTIBODY CONCENTRATIONS ON IN VITRO LYMPHOCYTE CYTOTOXICITY IN THE MOLONEY SARCOMA VIRUS SYSTEM (1972) (82)
- Killer T cells in a Burkitt's lymphoma biopsy (1975) (81)
- Characterization of cytotoxic human lymphocyte subpopulations: the role of Fc-receptor-carrying cells. (1977) (80)
- MHC class‐I‐restricted auto‐tumor‐specific CD4+CD8 −T‐cell clones established from autologous mixed lymphocyte‐tumor‐cell culture (MLTC) (1992) (78)
- The estimation of nucleic acids in individual isolated nuclei of ascites tumors by ultraviolet microspectrophotometry and its comparison with the chemical analysis. (1952) (76)
- Cancer immunotherapy: are the results discouraging? Can they be improved? (1992) (76)
- Cellular immunity against tumor‐associated antigens in humans: Lymphocyte stimulation and skin reaction (1974) (76)
- Antigenic properties of other experimental tumors. (1962) (74)
- SURFACE IgM SPECIFICITY ON CELLS DERIVED FROM A BURKITT'S LYMPHOMA (1967) (74)
- Effect of interferon-alpha 1 from E. coli on some cell functions. (1980) (71)
- Gradual transformation of solid into ascites tumors; evidence favoring the mutation-selection theory. (1955) (71)
- STAT6 signaling pathway activated by the cytokines IL-4 and IL-13 induces expression of the Epstein-Barr virus-encoded protein LMP-1 in absence of EBNA-2: implications for the type II EBV latent gene expression in Hodgkin lymphoma. (2011) (70)
- Antibody-dependent lymphocyte cytotoxicity in the murine sarcoma virus system: activity of IgM and IgG with specificity for MLV determined antigen(s). (1975) (69)
- Search for host defenses in Burkitt lymphoma: membrane immunofluorescence tests on biopsies and tissue culture lines. (1967) (68)
- IL-21 imposes a type II EBV gene expression on type III and type I B cells by the repression of C- and activation of LMP-1-promoter (2009) (67)
- Carbazole is a naturally occurring inhibitor of angiogenesis and inflammation isolated from antipsoriatic coal tar. (2006) (62)
- The nucleic acid content of mouse ascites tumor cells (1950) (62)
- Surface immunoglobulin-moieties on lymphoid cells. (1970) (62)
- The “natural killer” cell in the mouse does not require H‐2 homology and is not directed against type or group‐specific antigens of murine c viral proteins (1976) (62)
- The transformation of a solid transplantable mouse carcinoma into an "ascites tumor". (1951) (61)
- Interplay among viral antigens, cellular pathways and tumor microenvironment in the pathogenesis of EBV-driven lymphomas. (2013) (60)
- Rejectability of virus-induced tumors and nonrejectability of spontaneous tumors: a lesson in contrasts. (1977) (59)
- Lymphoblastoid cell line with B1 cell characteristics established from a chronic lymphocytic leukemia clone by in vitro EBV infection (2012) (58)
- MHC antigens on human tumors. (1991) (56)
- Cytochemical studies on some effects of x-radiation on three ascites tumors. (1958) (55)
- Concomitant increase of LMP1 and CD25 (IL‐2‐receptor α) expression induced by IL‐10 in the EBV‐positive NK lines SNK6 and KAI3 (2006) (54)
- Morphological changes, cell aggregation and cell membrane alterations caused by phorbol 12,13‐dibutyrate in human blood lymphocytes (1982) (54)
- Endogenous TGF‐β contributes to the induction of the EBV lytic cycle in two burkitt lymphoma cell lines (1994) (53)
- The lymphocyte response to a primary viral neoplasm (MSV) through its entire course in BALB/c mice (1972) (53)
- Monocytes enhance cell proliferation and LMP1 expression of nasal natural killer/T‐cell lymphoma cells by cell contact‐dependent interaction through membrane‐bound IL‐15 (2012) (52)
- Characterization of human lymphocyte subpopulations for cytotoxicity against tumor‐derived monolayer cultures (1977) (52)
- Activated T cells in the synovial fluid of arthritic patients: characterization and comparison with in vitro activated human and murine T cells in cooperation with monocytes in cytotoxicity. (1979) (51)
- The effect of storage on the nucleic acid content and virulence of mouse ascites tumor (1950) (51)
- Restricted autologous lymphocytotoxicity in lung neoplasia. (1978) (51)
- Human tumor-lymphocyte interaction in vitro. VI. Specificity of primary and secondary autologous lymphocyte-mediated cytotoxicity. (1979) (50)
- Immunotherapeutic approaches to the management of neoplasms. (1972) (50)
- A Spectrum of Mutations in SH2D1A That Causes X-linked Lymphoproliferative Disease and Other Epstein-Barr Virus-associated Illnesses (2002) (50)
- Leukotriene B4 plays a pivotal role in CD40-dependent activation of chronic B lymphocytic leukemia cells. (2004) (50)
- Separation and characteristics of tumor-infiltrating lymphocytes in man. (1980) (49)
- Selectively down-regulated expression of major histocompatibility complex class I alleles in human solid tumors. (1993) (49)
- Histocompatibility changes in tumors. (1958) (48)
- In vitro generation of cytotoxicity against autologous human tumour biopsy cells (1978) (48)
- SH2D1A and slam protein expression in human lymphocytes and derived cell lines (2000) (48)
- Surface immunoglobulins on Burkitt's lymphoma biopsy cells from 91 patients (1980) (48)
- Action of natural killer cells and macrophages in cancer. (1993) (46)
- Cell surface localized IgM-kappa immunoglobulin reactivity in a case of chronic lymphocytic leukaemia. (1970) (46)
- Studies on murine sarcoma virus: antigenic characterization of murine sarcoma virus induced tumor cells (1969) (46)
- Surveillance against tumors--is it mainly immunological? (2005) (46)
- Cytokine mediated induction of the major Epstein-Barr virus (EBV)-encoded transforming protein, LMP-1. (2006) (45)
- Natural species-restricted attachment of human and murine T lymphocytes to various cells. (1978) (45)
- Expression of the adhesion molecule ICAM-1 and major histocompatibility complex class I antigens on human tumor cells is required for their interaction with autologous lymphocytes in vitro (2005) (45)
- Complement-dependent cellular cytotoxicity: lymphoblastoid lines that activate complement component 3 (C3) and express C3 receptors have increased sensitivity to lymphocyte-mediated lysis in the presence of fresh human serum. (1985) (44)
- CHARACTERIZATION OF IMMUNOGLOBULIN STRUCTURES FROM THE SURFACE OF CHRONIC LYMPHOCYTIC LEUKEMIA CELLS (1971) (43)
- Studies of burkitt lymphoma cells. I. Establishment of a cell line (B35M) and its characteristics (1967) (43)
- Target selectivity of interferon-induced human killer lymphocytes related to their Fc receptor expression. (1980) (43)
- Tumor biopsy cells participating in systems in which cytotoxicity of lymphocytes is generated. Autologous and allogeneic studies (1981) (43)
- The proapoptotic function of SAP provides a clue to the clinical picture of X-linked lymphoproliferative disease (2009) (42)
- Studies of sublines selected for loss of HLA expression from an EBV-transformed lymphoblastoid cell line. Changes in sensitivity to cytotoxic T cells activated by allostimulation and natural killer cells activated by IFN or IL-2. (1989) (41)
- Comparative study of alkaline phosphatase activity in lymphocytes, mitogen-induced blasts, lymphoblastoid cell lines, acute myeloid leukemia, and chronic lymphatic leukemia cells. (1976) (41)
- Cell-surface antigens induced by RNA tumour viruses (1979) (41)
- Human tumor‐lymphocyte interaction in vitro. III. T lymphocytes in autologous tumor stimulation (ATS) (1978) (41)
- Paired Epstein‐Barr virus (EBV)‐negative and EBV‐converted Burkitt lymphoma lines: Stimulatory capacity in allogeneic mixed lymphocyte cultures (1987) (41)
- Spleen‐cell reactivity against transplanted neurogenic rat tumors induced by ethylnitrosourea: Uncovering of tumor specificity after removal of complement‐receptor‐bearing lymphocytes (1975) (40)
- Are methylcholanthrene‐induced sarcoma‐associated, rejection‐inducing (TSTA) antigens, modified forms of H‐2 or linked determinants? (1975) (40)
- The elevated natural killer sensitivity of targets carrying surface-attached C3 fragments require the availability of the iC3b receptor (CR3) on the effectors. (1988) (40)
- Contribution of CR3, CD11b/CD18 to cytolysis by human NK cells. (1990) (39)
- Genetic Studies of the Relationship of Tumour–Host Cells: Detection of an Allelic Difference at a Single Gene Locus in a Small Fraction of a Large Tumour-Cell Population (1956) (39)
- In vitro „education”︁ on autologous human sarcoma generates non‐specific killer cells (1975) (39)
- Soluble factors produced by activated CD4+ T cells modulate EBV latency (2012) (38)
- Treatment of Burkitt's lymphoma. (1968) (37)
- Characterization of the phorbol 12,13-dibutyrate (P(Bu)2) induced binding between human lymphocytes. (1983) (37)
- Expression of membrane‐bound IgM and HLA antigens on lymphoblastoid cells in different stages of the cell cycle (1974) (37)
- Human ex vivo carcinoma cells produce transforming growth factor β and thereby can inhibit lymphocyte functions in vitro (1997) (36)
- The immune response to primary moloney sarcoma virus tumors in BALB/C mice: Cellular and humoral activity of long‐term regressors (1974) (36)
- Human T lymphocytes become glucocorticoid-sensitive upon immune activation. (1980) (36)
- In vitro EBV‐infected subline of KMH2, derived from Hodgkin lymphoma, expresses only EBNA‐1, while CD40 ligand and IL‐4 induce LMP‐1 but not EBNA‐2 (2005) (36)
- Reversion of tumorigenicity and decreased agarose clonability after EBV conversion of an igh/myc translocation‐carrying be line (1989) (36)
- Endogenous TGF-beta contributes to the induction of the EBV lytic cycle in two Burkitt lymphoma cell lines. (1994) (36)
- Expression of the complement regulatory proteins CD21, CD55 and CD59 on Burkitt lymphoma lines: their role in sensitivity to human serum‐mediated lysis (1992) (36)
- Detection of cell surface antigens on monolayer cells. I. The application of immune adherence on a micro scale. (1970) (36)
- Further studies on the membrane immunofluorescence reaction of Burkitt lymphoma cells (1967) (35)
- Gradual transformation of solid into ascites tumors permanent difference between the original and the transformed sublines. (1954) (35)
- SH2D1A expression in Burkitt lymphoma cells is restricted to EBV positive group I lines and is downregulated in parallel with immunoblastic transformation (2002) (35)
- Cultivation with K562 cells leads to blastogenesis and increased cytotoxicity with changed properties of the active cells when compared to fresh lymphocytes. (1978) (35)
- Synthesis of immunoglobulins by biopsied tissues and cell lines from Burkitt's lymphoma. (1972) (35)
- Activation of B lymphocytes by Epstein‐Barr virus/CR2 receptor interaction (1987) (34)
- Immunological Tolerance of Neonatally Infected Mice to the Moloney Leukaemia Virus (1966) (34)
- Distinction of anti-K562 and anti-allocytotoxicity in in vitro-stimulated populations of human lymphocytes. (1979) (34)
- Immunological control of human lymphoma: discussion. (1976) (34)
- Antinuclear reactivity of sera in patients with leukemia and other neoplastic diseases. (1975) (33)
- SH2D1A and SLAM protein expression in human lymphocytes and derived cell lines. (2000) (33)
- Further studies on isoantigenic variation in mouse carcinomas and sarcomas. (1960) (33)
- The role of blocking antibodies in immunological enhancement. (1971) (33)
- Demonstration of host resistance against sarcomas induced by implantation of cellophane films in isologous (syngeneic) recipients. (1963) (33)
- Induction of the EBV cycle in B‐lymphocyte‐derived lines is accompanied by increased natural killer (NK) sensitivity and the expression of EBV‐related antigen(s) detected by the ADCC reaction (1980) (33)
- Isolation of 7S IgM and kappa chains from the surface membrane of tissue culture cells derived from a Burkitt lymphoma. (1971) (32)
- Activated T lymphocytes in infiltrates and draining lymph nodes of nasopharyngeal carcinoma (1980) (32)
- Effect of heterologous antilymphoid-cell serum on tumor isografts and viral leukemogenesis. (1967) (32)
- Differential expression of hla antigen of HLA anigens on human B‐cell lines of normal and malignant origin: A consequence of immune surveillance or a phenotypic vestige of the progenitor cells? (1988) (32)
- Immunization of mice with syngeneic Moloney lymphoma cells induces separate antibodies against virion envelope glycoprotein and virus- induced cell surface antigens (1977) (32)
- Antitumour activity in vitro dependent on immune B lymphocytes. (1973) (32)
- EBV genome carrying B lymphocytes that express the nuclear protein EBNA-2 but not LMP-1 (2013) (31)
- T Cells Modulate Epstein-Barr Virus Latency Phenotypes during Infection of Humanized Mice (2014) (31)
- Antibody response and leukemia development in mice inoculated neonatally with the Moloney virus. (1965) (30)
- Immune responses to weakly immunogenic virally induced tumors I. Overcoming low responsiveness by priming mice with a syngeneic in vitro tumor line or allogeneic cross‐reactive tumor (1978) (30)
- HLA-A0201 and HLA-B7 binding peptides in the EBV-encoded EBNA-1, EBNA-2 and BZLF-1 proteins detected in the MHC class I stabilization assay. Low proportion of binding motifs for several HLA class I alleles in EBNA-1. (1995) (30)
- Human leukemia-associated anti-nuclear reactivity. (1974) (29)
- Epstein-Barr virus (EBV) antigens processed and presented by B cells, B blasts, and macrophages trigger T-cell-mediated inhibition of EBV-induced B-cell transformation (1990) (29)
- Activated T cells in the synovial fluid of arthritic patients. II. In vitro activation of the autologous blood lymphocytes. (1981) (29)
- The X-linked lymphoproliferative disease gene product SAP is expressed in activated T and NK cells. (2002) (29)
- Reduced expression of major histocompatibility complex class I free heavy chains and enhanced sensitivity to natural killer cells after incubation of human lymphoid lines with β2‐microglobulin (1993) (29)
- CYTOTOXIC POTENTIAL OF MOUSE SPLEEN CELLS ON H-2 ANTIBODY-TREATED TARGET CELLS (1973) (29)
- An established Burkitt's lymphoma line with cell membrane IgG. (1975) (29)
- Burkitt lymphoma cells in expressing EBNA-1 infected with Epstein-Barr virus resembles A subpopulation of normal B cells latently (1995) (28)
- Interferon γ is a STAT1-dependent direct inducer of BCL6 expression in imatinib-treated chronic myeloid leukemia cells (2017) (28)
- Surface antigens and release of virus in hybrid cells produced by the fusion of A9 fibroblasts with Moloney Lymphoma cells. (1971) (28)
- Ligand inhibition studies on the role of Fc receptors in antibody-dependent cell-mediated cytotoxicity. (1984) (28)
- Expression of SH2D1A in five classical Hodgkin's disease‐derived cell lines (2003) (28)
- Immediate transformation of solid into ascites tumors; studies on a mammary carcinoma of an inbred mouse strain. (1955) (28)
- Phorbol 12,13-dibutyrate (P(Bu)2)-treated human blood mononuclear cells bind to each other. (1983) (28)
- Xenotransplantation of a Burkitt Lymphoma Culture Line with Surface Immunoglobulin Specificity (1969) (28)
- Natural cytotoxicity of human blood lymphocytes and monocytes and their cytotoxic factors: effect of interferon on target cell susceptibility. (1985) (27)
- Human monoclonal antibodies produced by immortalization with Epstein-Barr virus. (1981) (26)
- LYMPHOCYTE STIMULATION TEST FOR DETECTION OF TUMOR SPECIFIC REACTIVITY IN HUMANS (1976) (26)
- Clonality and methylation status of the epstein‐barr virus (EBV) genomes in IN V7W‐infected EBV‐carrying chronic lymphocytic leukemia (CLL) cell lines (2007) (26)
- EBV-related cytotoxicity of Fc receptor negative T lymphocytes separated from the blood of infectious mononucleosis patients. (1978) (26)
- Effect of the ebna‐2 gene on the surface antigen phenotype of transfected ebv‐negative B‐lymphoma lines (1990) (26)
- Wild-type p53 activates SAP expression in lymphoid cells (2004) (26)
- A repetitive sequence of Epstein-Barr virus nuclear antigen 6 comprises overlapping T cell epitopes which induce HLA-DR-restricted CD4(+) T lymphocytes. (2000) (26)
- In vitro generation of K562 killers in human T-lymphocyte subsets. (1980) (26)
- Mouse Antibody Production Test for the Assay of the Moloney Virus (1964) (26)
- PSK and Trx80 inhibit B-cell growth in EBV-infected cord blood mononuclear cells through T cells activated by the monocyte products IL-15 and IL-12. (2005) (26)
- Studies on the mechanism of isoantigenic variant formation in heterozygous mouse tumors. I. Behavior of H-2 antigens D and K: quantitative absorption tests on mouse sarcomas. (1961) (25)
- Alternative complement pathway activation by HIV infected cells: C3 fixation does not lead to complement lysis but enhances NK sensitivity. (1991) (25)
- Human tumor—lymphocyte interaction in vitro: Blastogenesis correlated to detectable immunoglobulin in the biopsy (1975) (25)
- Cytomegalovirus-Seropositive Children Show Inhibition of In Vitro EBV Infection That Is Associated with CD8+CD57+ T Cell Enrichment and IFN-γ (2013) (25)
- Requirement of leukocytic cell adhesion molecules (CD11a-c/CD18) in the enhanced NK lysis of iC3b-opsonized targets. (1989) (25)
- Cytogenetic, serologic, and transplantation studies on a heterozygous tumor and its derived variant sublines. (1958) (25)
- Epstein-Barr virus-infected B-chronic lymphocyte leukemia cells express the virally encoded nuclear proteins but they do not enter the cell cycle. (2000) (25)
- Permanent modification (mutation?) of a histocompatibility gene in a heterozygous tumor. (1957) (25)
- THE INFLUENCE OF THE PARTNER CELL ON THE PRODUCTION OF L VIRUS AND THE EXPRESSION OF VIRAL SURFACE ANTIGEN IN HYBRID CELLS (1973) (25)
- EBV infection of B-CLL cells in vitro potentiates their allostimulatory capacity if accompanied by acquisition of the activated phenotype. (1994) (24)
- Histopathologic studies of peritoneal implantation and lung metastasis at different stages of the gradual transformation of the MCIM mouse sarcoma into ascites form. (1957) (24)
- 12-O- tetradecanoylphorbol- 13 acetate (TPA) treatment elevates the natural killer (NK) sensitivity of certain human lymphoid lines. (1981) (24)
- Functional characteristics of the intercellular adhesion molecule-1 (CD54) expressed on cytotoxic human blood lymphocytes. (1990) (24)
- B‐CLL cells with unusual properties (1997) (24)
- Specificity of homograft rejection in vivo, assessed by inoculation of artificially mixed compatible and incompatible tumor cells. (1972) (24)
- Experiences with a frozen tumor bank. (1957) (24)
- LMP-1, the Epstein-Barr virus-encoded oncogene with a B cell activating mechanism similar to CD40. (1999) (24)
- Immunologic approaches to various types of cancer with the use of BCG and purified protein derivatives. (1973) (24)
- Quantification of immunofluorescence on individual erythrocytes coated with varying amounts of antigen. (1970) (24)
- Deficiency of the proapoptotic SAP function in X-linked lymphoproliferative disease aggravates Epstein-Barr virus (EBV) induced mononucleosis and promotes lymphoma development. (2010) (24)
- Skin and tumor grafting in coisogenic resistant lines of mice and their hybrids. (1960) (23)
- The humoral antibody response to a primary viral neoplasm (MSV) through its entire course in BALB/c mice (1973) (23)
- Epstein-barr virus can infect B-chronic lymphocytic leukemia cells but it does not orchestrate the cell cycle regulatory proteins. (2001) (23)
- Simultaneous detection of the two main proliferation driving EBV encoded proteins, EBNA-2 and LMP-1 in single B cells. (2012) (23)
- Human thyroglobulin and thyroid extract as specific stimulators of sensitized lymphocytes. (1971) (23)
- Activation of human blood lymphocytes and monocytes by the streptococcal preparation OK432: enhanced generation of soluble cytotoxic factors. (1985) (23)
- Lysis of autologous tumor cells by blood lymphocytes tested at the time of surgery (2004) (22)
- Human tumor — Lymphocyte interaction in vitro (1978) (22)
- On the substrate induced enzyme formation in animal cells cultured in vitro. (1960) (21)
- Somatic hybrids between a high NK-sensitive lymphoid (YACIR) and several low sensitive sarcoma or L-cell-derived mouse lines exhibit low sensitivity (1980) (21)
- p53 contributes to T cell homeostasis through the induction of pro-apoptotic SAP (2012) (21)
- Correlation between lymphocyte-mediated auto-tumor reactivities and clinical course (1983) (21)
- Differential survival of solid tumor cells after inoculation into established ascites tumors. (1954) (21)
- Surface Markers on Human B and T Lymphocytes (1975) (21)
- The polysaccharide K (PSK) potentiates in vitro activation of the cytotoxic function in human blood lymphocytes by autologous tumour cells (2005) (21)
- Expression of MHC‐class‐I antigens in human carcinomas and sarcomas analyzed by isoelectric focusing (1991) (20)
- Lysis of tumor biopsy cells by blood lymphocyte subsets of various densities. Autologous and allogeneic studies (1984) (20)
- Natural cytotoxicity of human blood monocytes and natural killer cells and their cytotoxic factors: Discriminating effects of actinomycin D (1985) (20)
- Prophylactic intervention in radiation-leukemia-virus-induced murine lymphoma by the biological response modifier polysaccharide K (1995) (20)
- The viability and the average desoxypentosenucleic acid content of micronuclei-containing cells produced by colchicine treatment in the Ehrlich ascites tumor. (1952) (20)
- Cytotoxicity of human peripheral lymphocytes for glioma, osteosarcoma, and glia cell lines. (1973) (20)
- Interferon suppresses antigen- and mitogen-induced leukocyte migration inhibition (1980) (20)
- Surface antigen expression in malignant sublines derived from hybrid cells of low malignancy. (1971) (20)
- Factorial analysis of the reactivity of C57BL females against isologous male skin grafts. (1961) (20)
- Immune responses to weakly immunogenic virally induced tumors II. Suppressive effects of the in vivo carried tumor YAC (1978) (20)
- Binding characteristics and isotype specificity of Fc receptors on K cells. (1986) (19)
- Correlation between lymphocyte-mediated auto-tumor reactivities and the clinical course (1983) (19)
- Latency Type-Dependent Modulation of Epstein-Barr Virus-Encoded Latent Membrane Protein 1 Expression by Type I Interferons in B Cells (2012) (19)
- SURFACE IMMUNOGLOBULIN‐MOIETIES ON LYMPHOID CELLS * (1971) (18)
- Inhibition of DNA Synthesis of Target Cells in vitro by Sensitized Lymphocytes (1967) (18)
- B cell activation by the nontransforming P3HR‐1 substrain of the Epstein‐Barr virus (EBV) (1986) (18)
- Auto-tumor recognition following in vitro induction of MHC antigen expression on solid human tumors: stimulation of lymphocytes and generation of cytotoxicity against the original MHC-antigen-negative tumor cells (2004) (18)
- Increased expression of MHC class I molecules on human cells after short time IFN-γ treatment (1993) (18)
- Leukotriene B4 activates T cells that inhibit B-cell proliferation in EBV-infected cord blood-derived mononuclear cell cultures. (2008) (18)
- STUDIES ON THE MECHANISM OF ISOANTIGENIC VARIANT FORMATION IN HETEROZYGOUS MOUSE TUMORS. III. BEHAVIOR OF H-2 ANTIGENS D AND K WHEN LOCATED IN THE TRANS POSITION. (1964) (18)
- Natural and activated cytotoxic lymphocytes which act on autologous and allogeneic tumor cells (1981) (18)
- Molecular characterization of neoplastic and normal “sister” lymphoblastoid B-cell lines from chronic lymphocytic leukemia (2013) (17)
- Autologous mixed lymphocyte‐tumor reaction and autologous mixed lymphocyte reaction. II. Generation of specific and non‐specific killer T cells capable of lysing autologous tumor (1988) (17)
- Tissue culture assay for Moloney leukemia virus. (1970) (17)
- The complexity of the Epstein-Barr virus infection in humans (2008) (17)
- Correlation between the presence of surface localized immunoglobulin (Ig) and the histological type of human malignant lymphomas. (1976) (17)
- The changing faces of EBV research. (1984) (17)
- Suppression of T-cell response in autologous mixed lymphocyte-tumor culture by large granular lymphocytes. (1986) (17)
- Induction of tumor cell rejection in the low responsive YAC-lymphoma strain A host combination by immunization with somatic cell hybrids. (1979) (17)
- Studies on the substrate-induced arginase synthesis in animal cell strains cultured in vitro. (1961) (17)
- Expression of Helix pomatia (HP) haemagglutinin receptors on cytolytic lymphocytes activated in mixed cultures. (1983) (17)
- Type I interferons directly down-regulate BCL-6 in primary and transformed germinal center B cells: differential regulation in B cell lines derived from endemic or sporadic Burkitt's lymphoma. (2012) (17)
- Auto-tumor immunity in patients with solid tumors: participation of CD3 complex and MHC class I antigens in the lytic interaction. (1987) (17)
- Nucleic Acid Content of Tumour Cells (1950) (16)
- Antigenic Behavior of Moloney Lymphomas: Independence of Virus Release and Imunosensitivity (1964) (16)
- Combined treatment with interferon (IFN)-γ and tumor necrosis factor (TNF)-α up-regulates the expression of HLA class I determinants in Burkitt lymphoma lines (1988) (16)
- Activation of human blood lymphocyte subsets for cytotoxic potential. (1982) (16)
- The MEC1 and MEC2 Lines Represent Two CLL Subclones in Different Stages of Progression towards Prolymphocytic Leukemia (2014) (16)
- To the genesis of Burkitt lymphoma: regulation of apoptosis by EBNA-1 and SAP may determine the fate of Ig-myc translocation carrying B lymphocytes. (2009) (16)
- Effect of cyclosporin‐A (CsA) on the ability of T lymphocyte subsets to inhibit the proliferation of autologous EBV‐transformed B cells (1985) (16)
- Differential recognition of tumor-derived and in vitro Epstein-Barr virus-transformed B-cell lines by fetal calf serum-specific T4-positive cytotoxic T-lymphocyte clones. (1986) (16)
- Intranuclear localization of the transcription coadaptor CBP/p300 and the transcription factor RBP-Jk in relation to EBNA-2 and -5 in B lymphocytes. (2001) (16)
- Recognition of Autologous Tumour Cells by Blood Lymphocytes in Patients with Lung Cancer (1987) (16)
- Growth of small compatible tumor implants in presence of admixed radiation‐killed or incompatible tumor cells (1959) (16)
- The lymphocyte response to primary moloney sarcoma virus tumors: Definition of a non‐specific component of the in vitro cellular hyporeactivity of tumor‐bearing hosts (1974) (15)
- The evolution of independence from specific growth stimulation and inhibition in mammalian tumour-cell populations. (1957) (15)
- Studies on the relations between virus release and cellular immunosensitivity in Moloney lymphomas. (1969) (15)
- Effect of transforming growth factor-beta 1 and -beta 2 on the proliferation of Burkitt lymphoma and lymphoblastoid cell lines. (1991) (15)
- Upregulation of LMP1 Expression by Histone Deacetylase Inhibitors in an EBV Carrying NPC Cell Line (2004) (15)
- Tumor‐bound immunoglobulins. I. Further analysis of the characteristics of binding of immunoglobulins to In vivo‐grown tumor cells (1976) (15)
- Activation of cytotoxic activity of human blood lymphocytes by tumor-promoting compounds. (1984) (14)
- The tumor promoter phorbol-12,13-dibutyrate [P(Bu)2] stimulates cytotoxic activity of human blood lymphocytes. (1983) (14)
- T‐cell‐mediated inhibition of EBV‐induced B‐cell transformation: Recognition of virus particles (1988) (14)
- The cell surface in immune response. (1970) (14)
- Human T lymphocyte receptors for sheep red blood cells and specific antigens: are they identical sites on the cell membrane? (1977) (14)
- RELATIONSHIP BETWEEN HOST RANGE AND ISOANTIGENIC PROPERTIES IN DIFFERENT SUBLINES OF THE SAME SARCOMA. (1963) (14)
- Virus-associated surface antigens on L cells and Moloney lymphoma cells. (1974) (14)
- Tumour immunology; escape mechanisms. (1972) (14)
- Detection of cell surface antigens on monolayer cells. II. The application of mixed haemadsorption on a micro scale. (1970) (14)
- Human blood lymphocyte subsets separated on the basis of nylon adherence, SRBC and EA rosetting: natural cytotoxicity and characterization with monoclonal reagents. (1982) (14)
- Human blood lymphocyte fractionation with special attention to their cytotoxic potential. (1978) (14)
- APPLICATIONS OF MICROSPECTROFLUOROMETRY IN QUANTITATION OF IMMUNOFLUORESCENCE ON SINGLE CELLS * (1971) (13)
- SH2D1A expression reflects activation of T and NK cells in cord blood lymphocytes infected with EBV and treated with the immunomodulator PSK. (2002) (13)
- Restricted expression of EBV encoded proteins in in vitro infected CLL cells. (2010) (13)
- Chronic lymphoid leukemia cells are highly sensitive to the combination of prednisolone and daunorubicin, but much less to doxorubicin or epirubicin. (2010) (13)
- A trypsin‐like serine protease activity on activated human B cells and various B cell lines (1992) (13)
- Rejectability of virus-induced tumors and nonrejectability of spontaneous tumors-a lesson in contrasts. (1977) (13)
- DR antigens expressed on tumor cells do not contribute to the blastogenetic response of autologous T cells (2004) (13)
- Killing often spoken of as natural Naming in clonal terms…. (1983) (13)
- Fc receptors on human blood B lymphocytes. (1977) (12)
- Comparison of highly NK active human lymphocyte subsets separated by various procedures involving E, EA rosetting, density gradients and adherence to immune complexes. (1983) (12)
- Autologous mixed lymphocyte‐tumor reaction and autologous mixed lymphocyte reaction. I. Proliferation of two distinct T‐cell subsets (1987) (12)
- Importance of MHC antigen expression on solid tumors in the in vitro interaction with autologous blood lymphocytes (2004) (12)
- Induction of the lytic viral cycle in Epstein Barr virus carrying Burkitt lymphoma lines is accompanied by increased expression of major histocompatibility complex molecules. (1993) (12)
- Loss of net negative surface charge during MLC stimulation of human T lymphocytes: correlation to "stable" E-rosette formation and natural attachment to normal and malignant target cells. (1979) (12)
- cMyc-p53 feedback mechanism regulates the dynamics of T lymphocytes in the immune response (2016) (12)
- Isoantigenicity of x-ray-inactivated implants of a homotransplantable and a non-homotransplantable mouse sarcoma. (1959) (12)
- MEMBRANE IMMUNOFLUORESCENCE ON CULTURED INDICATOR CELLS AS A MEASURE OF VIRUS PRODUCTION BY MOUSE L CELLS AND BY TWO MOLONEY LYMPHOMA SUBLINES DIFFERING IN IMMUNOSENSITIVITY * (1971) (12)
- Natural killer activity of human blood lymphocytes. (1982) (12)
- Detection of two epstein‐barr‐virus (EBV)‐carrying leukemic cell clones in a patient with chronic lymphocytic leukemia (CLL) (1995) (12)
- Characterization of blood mononuclear cells reacting with K 562 cells after yellow fever vaccination. (1982) (12)
- Potentiation of NK cytotoxicity by antibody-C3b/iC3b heteroconjugates. (1990) (12)
- Activation of innate immunity by the leukotriene B 4 inhibits EBV induced B-cell transformation in cord-blood derived mononuclear cultures. (2008) (12)
- SPECIFICITY OF FRESH AND ACTIVATED HUMAN CYTOTOXIC LYMPHOCYTES (1982) (12)
- Biphasic effect of transforming growth factor-beta on Epstein-Barr virus-induced activation of human tonsillar B cells. (1994) (12)
- Functional studies on tumor-infiltrating lymphocytes in man. (1977) (12)
- Lymphocyte stimulation by autologous tumor cells in the presence of serum from the same patient or from healthy donors (1975) (11)
- Effect of TGF‐β1 on the ebv‐induced transformation of human lymphocyte cultures (1992) (11)
- Lymphocytes of Hodgkin's biopsies exhibit: stable E-rosette formation, natural attachment and glucocorticoid sensitivity, similar to immunoactivated T cells. (1980) (11)
- Activated T lymphocytes within human solid tumors (1979) (11)
- EBNA promoter usage in ebv‐negative burkitt lymphoma cell lines converted with a neomycin‐resistant EBV strain (2001) (11)
- Tumor surveillance: expression of the transporter associated with antigen processing (TAP-1) in ex-vivo human tumor samples and its elevation by in vitro treatment with IFN-γ and TNF-α (1998) (11)
- Natural killer cells in cancer. (2006) (11)
- Lysis of autologous tumor cells by high‐density lymphocytes is potentiated by the streptococcal preparation OK432 (picibanil) (1986) (11)
- Immunology: Sinking surveillance's flagship (1998) (11)
- The apoptosis modulating role of SAP (SLAM associated protein) contributes to the symptomatology of the X linked lymphoproliferative disease (2009) (11)
- Recognition of B-CLL cells experimentally infected with EBV by autologous T lymphocytes. (1998) (11)
- Presence of erythrocytic components in the K562 cell line (1979) (10)
- Epstein-Barr virus-carrying B cells in the blood during acute infectious mononucleosis give rise to lymphoblastoid lines in vitro by release of transforming virus and by proliferation. (1990) (10)
- Red-cell bound anti-A is more efficient than anti-B in competition for fluid phase complement. (1993) (10)
- Lymphocytes stimulated by allogeneic B cell lines cleave the third component of complement and fix C3 fragments. Their nonspecific lytic capacity is elevated against complement receptor type 2-carrying targets. (1989) (10)
- C3d-mediated negative and positive signals on the proliferation of human B cells separated from blood. (1990) (10)
- Complement-dependent cellular cytotoxicity due to alternative pathway C3 activation by the target cell membrane. (1984) (10)
- Cation requirement of natural, in-vitro generated and antibody dependent killing exerted by human lymphocytes. (1979) (10)
- Interaction of antibody and cell surface localized antigen (1976) (10)
- CYTOTOXIC AND CYTOSTATIC ACTIVITY OF HUMAN LARGE GRANULAR LYMPHOCYTES AGAINST ALLOGENEIC TUMOR BIOPSY CELLS AND AUTOLOGOUS EBV INFECTED B LYMPHOCYTES (1982) (10)
- Cell-mediated immunity against epstein-barr virus infected B lymphocytes (2004) (10)
- How one thing has led to another. (1989) (10)
- Defective cytotoxic T-cell generation in Moloney murine sarcoma virus-infected A/Sn mice. (1980) (10)
- Epigenetic mechanisms do not control viral latency III in primary effusion lymphoma cells infected with a recombinant Epstein–Barr virus (2005) (10)
- EBV Infection Induces Expression of the Transcription Factors ATF-2/c-Jun in B Lymphocytes but not in B-CLL Cells (2005) (10)
- Tumor-bound immunoglobulins: an in vivo phenomenon of masked specificity. (1976) (10)
- The effect of synthetic peptides corresponding to Fc sequences in human IgG 1 on various steps in the B cell activation pathway (1988) (9)
- Pathogenesis of Epstein-Barr virus (EBV)-carrying lymphomas. (2006) (9)
- Host defenses in leukemia and Burkitt's tumor (1968) (9)
- PROTECTIVE EFFECT OF MURINE SARCOMA VIRUS‐SUPEREVFECTED MOUSE TUMOR CELLS AGAINST OUTGROWTH OF CORRESPONDING NONINFECTED TUMOR (1978) (9)
- Elevated NK-mediated lysis of Raji and Daudi cells carrying fixed iC3b fragments. (1989) (9)
- Elevated NK sensitivity of Raji cells carrying acceptor-bound C3 fragments. (1988) (9)
- Correlation between the growth‐inhibitory effect of TGF‐β1 and phenotypic characteristics in a panel of B‐cell lines (1993) (9)
- Structural abnormalities in chromosome 15 in cell lines with reduced expression of beta-2 microglobulin (1977) (9)
- Alternative pathway of complement activation by stimulated T lymphocytes I. Binding of C3 fragments (1987) (9)
- Spontaneous and PHA-induced rosetting of human blood, tonsil lymphocytes and MLC blasts with sheep, human and horse erythrocytes. (1976) (8)
- Alternative complement pathway activation by CD4+ T cells of HIV infected individuals: a possible role in AIDS pathogenesis. (1994) (8)
- Alternative pathway of complement activation by stimulated T lymphocytes. II. Elevation of cytotoxic potential against complement receptor‐carrying cell lines (1987) (8)
- Human T cell growth factor (TCGF) produced by repeated stimulation of non-adherent human lymphocytes. (1982) (8)
- STUDIES ON THE EFFECT OF ISOANTISERUM ON MOUSE SARCOMA CELLS (1960) (8)
- 23 – THE METHODOLOGY OF MICROASSAY FOR CELL-MEDIATED IMMUNITY (MCI) (1971) (8)
- Effect of Interferon on Cell Proliferation and Generation of Cytotoxic Potential in Mixed Autologous and Allogeneic Lymphocyte Cultures (1983) (8)
- B-CLL cells experimentally infected with EBV enter DNA synthesis, produce cytokines and stimulate T-lymphocytes. (1996) (8)
- Contribution of activated C3 to lymphocyte-mediated cytolysis. (1986) (8)
- EBV infection of mitogen‐stimulated human B lymphocytes (1981) (8)
- Modulation of human blood lymphocyte cytotoxicity by the phorbol ester tumor promoter P(Bu)2: increase of target binding, impairment of effector recycling, and activation of lytic potential which is independent of IL-2. (1985) (8)
- Requirement of MHC class I antigen expression on human tumors for in vitro recognition by autologous blood lymphocytes. (1991) (7)
- Effect of immune factors on the motility of lymphoma cells. (1972) (7)
- An extractable nuclear antigen not attaching to tannic acid-treated erythrocytes. (1976) (7)
- Interferon γ is a strong, STAT1-dependent direct inducer of BCL6 expression in multiple myeloma cells. (2018) (7)
- Adjuvant immunotherapy in acute nonlymphocytic leukemia (1978) (7)
- EGNA-specific LIF production of human lymphocyte subsets. (1984) (7)
- Immune interferon (IFN-γ) production in autologous mixed cultures (1983) (7)
- Characteristics of murine C‐type viruses. III. Antigenic conversion and focus induction (1974) (7)
- Generation of cytotoxic factor by human large granular lymphocytes during interaction with autologous tumor cells: lysis of fresh human tumor cells. (1988) (7)
- Lysis of P3HR-1 cells induced to enter the viral cycle by antibody-dependent and independent immunological mechanisms. (1989) (7)
- Characteristics of murine C-type viruses. II. The behavior of viruses resident in various cell lines and their hybrids on BALB-3T3 and mouse embryo fibroblast cultures. (1974) (7)
- Effects of sodium butyrate on human chronic myelogenous leukaemia cell line K562 (reply) (1979) (7)
- Interferon-γ and Tumor Necrosis Factor-α Treatment of Ex Vivo Human Carcinoma Cells Potentiates Their Interaction with Allogeneic Lymphocytes (1996) (7)
- NATURAL AND ACTIVATED LYMPHOCYTE KILLERS WHICH AFFECT TUMOR CELLS1 (1980) (7)
- The role of thymus on autosensitization against syngeneic normal and malignant cells (1975) (6)
- Interactions in the complement-mediated lysis of blood group AB erythrocytes sensitized simultaneously with anti-A and anti-B monoclonal antibodies. (1993) (6)
- Murine Leukemia Virus Assay Techniques: A Comparative Study (1972) (6)
- Increased expression of MHC class I molecules on human cells after short time IFN-gamma treatment. (1993) (6)
- HRF20/CD59 complement regulatory protein expression is phenotype-dependent and inducible by the hypomethylating agent 5-azacytidine on Burkitt's lymphoma cell lines. (1993) (6)
- Demonstration of resistance against methyleholanthrene-inducedsarcomas in primary autochthonous hosts (1962) (6)
- Introduction: Immunotherapy of cancer in man, a reality. (1973) (6)
- Activation of B lymphocytes with human serum-treated zymosan. (1988) (6)
- Potentiation of T cell immunity against radiation-leukemia-virus-induced lymphoma by polysaccharide K (2005) (6)
- Human tumor cell migration. (1973) (6)
- Leukotriene B 4 plays a pivotal role in CD40-dependent activation of chronic B lymphocytic leukemia cells (2004) (6)
- Search for the critical characteristics of phenotypically different B cell lines, Burkitt lymphoma cells and lymphoblastoid cell lines, which determine differences in their functional interaction with allogeneic lymphocytes (2005) (6)
- Human Tumor-Lymphocyte Interaction in Vitro: Comparison of the Results with Autologous Tumor Stimulation (ATS) and Lymphocytotoxicity (ALC) (1979) (6)
- Lymphocyte stimulation by autochthonous human solid tumours. (1973) (6)
- Defective cell‐mediated response to EBV‐transformed B cells in a healthy individual with regular EBV antibody titers (1987) (6)
- Antibody-induced redistribution of surface antigen is independent of the amount of antigen and the cell cycle position. (1974) (5)
- Surface markers and functional characteristics of human blood lymphocytes residing in the operational "null" subset. (1978) (5)
- Perspectives in CancerResearch Conditioned Tumorigenicity of Activated Oncogenes1 (1986) (5)
- Lymphocyte-mediated lysis of tumor cells in vitro antigen-restricted clonal and unrestricted polyclonal effects (2004) (5)
- Auto-tumor lysis by blood lymphocytes in vitro (1989) (5)
- Effect of TGF-beta 1 on the EBV-induced transformation of human lymphocyte cultures. (1992) (5)
- Immunomodulatory effect of synthetic peptides corresponding to sequences within the CH2 and CH3 domain of human IgG1. (1988) (5)
- Central issues in present-day tumor immunology: interpretation of lymphocytotoxicity assays and the demonstration of auto-tumor-reactive lymphocytes in patients. (1981) (5)
- Assembly of MHC class I molecules in ex vivo carcinoma cells induced by IFN-gamma or by a binding peptide. (1992) (5)
- Role of H-2 antigens in the host response to methylcholanthrene-induced tumors (2004) (5)
- Migration of lymph node cells during the primary immune response. (1971) (5)
- Fluorometric quantitation of fluorescein-coupled antibodies attached to the cell membrane. (1969) (5)
- Search for disease-related cytotoxicity in mammary tumor patients. (1978) (4)
- N‐Alkaline Phosphatase: a Potential Disease Marker for Lymphoproliferative Disorders (1979) (4)
- Lysis of autologous tumor cells by blood lymphocytes activated in autologous mixed lymphocyte tumor cell culture — No correlation with the postsurgical clinical course (2004) (4)
- Correction: Exosomes Derived from Burkitt’s Lymphoma Cell Lines Induce Proliferation, Differentiation, and Class-Switch Recombination in B Cells (2019) (4)
- Mixed Agglutination between Established Burkitt Cell Lines and Fresh Biopsy Specimens (1967) (4)
- The role of humoral immunity and the contribution of the F1 anti-parental effect in the rejection of a moloney leukemia virus-induced lymphoma graft (2004) (4)
- Requirement of the CD8+ or CD4+ T lymphocyte subsets for the rejection of lymphoma and fibrosarcoma grafts studied in gene knockout hosts. (1998) (4)
- HLA‐B5‐restricted auto‐tumor‐specific cytotoxic T cells generated in mixed lymphocyte‐tumor‐cell culture (1992) (4)
- Leukocyte migration inhibitory factor production by activated lymphocytes representing immunological memory or virus-receptor interaction: response of T cell subsets to Epstein-Barr virus nuclear antigen, response of B cells to UV inactivated Epstein-Barr virus. (1985) (4)
- Antibodies in human sera against the Epstein-Barr virus encoded latent membrane protein (LMP). (1988) (4)
- Expression of H-2b alloantigens in a variant of a Moloney virus-induced YAC (H-2a) lymphoma. (1982) (4)
- Natural killer cells in cancer. (2006) (4)
- DIFFERENT SENSITIVITY OF B CELL LINES DERIVED FROM BURKITT LYMPHOMA (BL) AND NORMAL CELLS (LCL) TO CYTOTOXIC T CELL CLONES GENERATED BY AUTOLOGOUS AND ALLOGENEIC STIMULATION (1986) (4)
- Immunofluorometric Determinations of Surface Immunoglobulins of Individual Normal and Malignant Human Lymphoid Cells (1973) (4)
- Changes in cell surface properties during the in vivo growth of Moloney lymphoma. (1973) (4)
- Activation and fixation of C3 by human B cell lines is enhanced by interferon-gamma and tumor necrosis factor alpha. (1991) (4)
- The role of DNA hypomethylation, histone acetylation and in vivo protein-DNA binding in Epstein-Barr virus-induced CD23 upregulation. (2013) (4)
- Unsung Hero Robert C. Gallo (2009) (4)
- Reduced humoral and cellular cytotoxic sensitivity in major histocompatibility variants of the YAC (Moloney) lymphoma (2005) (4)
- Natural killer and tumor recognizing lymphocyte activity in tumor patients. (1978) (4)
- Differences in the competitive capacity of monoclonal antibody sensitized human A and B erythrocytes in complement mediated cytotoxicity. (1990) (3)
- Epstein-Barr Virus (EBV) Specific T and K Cell Cytotoxicity in vitro1 (1976) (3)
- Effect of immunization on the spread of transplanted mouse lymphoma cells. (1973) (3)
- Sensitivity of JLSV-9 cells to Moloney leukemia virus in relation to cell cycle. (1971) (3)
- COMMENT ON THE NOMENCLATURE OF LYMPHOCYTE MEDIATED CYTOTOXIC EFFECTS (1982) (3)
- Selective inhibitory effect of Hu-IFN-gamma on the agarose clonability of tumor-derived lymphoid cell lines. (1985) (3)
- Effect of TGF-beta on the proliferation of B cell lines and on the immortalisation of B cells by EBV. (1990) (3)
- Alloreactive cytotoxicity of interferon-triggered human lymphocytes detected with tumor biopsy targets (2004) (3)
- Recognition of transformed cells by autologous lymphocytes: a review. (1991) (3)
- Effects of isolated tumor lymphocytes alone and with adherent cells (2004) (3)
- Non-proliferative interactions of Epstein-Barr virus and human B lymphocytes. (2004) (3)
- Epstein Barr virus (EBV) carrying cells in blood of Hodgkin's disease (HD) and non-Hodgkin lymphoma (NHL) patients with high antibody titers against EBV capsid antigens (VCA). (1990) (3)
- Introduction: diagnosis and immunotherapy of cancer. (1972) (3)
- The rise and fall of central dogmas (2016) (3)
- The increased natural killer sensitivity of Epstein-Barr virus (EBV)-superinfected Raji cells is not due to the recognition of serologically determined EBV antigens by the effectors. (1982) (3)
- Contribution of activated C3 to lymphocyte-mediated target lysis: complement-dependent cellular cytotoxicity. (1984) (3)
- Variation in cell populations of transplanted tumors as indicated by studies on the ascites transformation. (1955) (3)
- Effector or target cell selection mediated by C3 bridges. (1987) (3)
- Lysis of CR2-carrying cells by natural killer cells and by activated T-lymphocytes is enhanced by C3 fragments. (1988) (3)
- The natural attachment of thymocytes and activated T lymphocytes to normal and malignant cells: an interspecies study. (1980) (3)
- Antibiotic Prophylaxis or Granulocyte-Colony Stimulating Factor Support in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation (2021) (3)
- Modification of Cell Differentiation, One of the Mechanisms in the Surveillance of Malignancy (2015) (2)
- Human Tumor-- Lymphocyte Interaction in vitro II . Conditions Which Improve the Capaelty of Biopsy Cells to Stimulate Autologous Lymphoeytes (2)
- Specificity of homograft rejection in vivo, assessed by inoculation of artificially mixed compatible and imcompatible tumor cells. (1972) (2)
- Immunogenicity and immunosensitivity of ex vivo human carcinomas: interferon γ and tumour necrosis factor α treatment of tumour cells potentiates their interaction with autologous blood lymphocytes (1995) (2)
- AUTO-TUMOR LYTIC POTENTIAL OF LYMPHOCYTES SEPARATED FROM HUMAN SOLID TUMORS (1982) (2)
- The use of histocompatibility genes as markers for the study of isoantigenic variation in populations of tumor cells. (1959) (2)
- Cellular Receptors for Epstein-Barr Virus (1989) (2)
- Experimental and clinical data for the role of NK-cells in immunosurveillance. (1984) (2)
- Storage, Utilization and Disposal of Hematopoietic Stem Cell Products in Multiple Myeloma Patients. (2020) (2)
- Surgace IgM specificity on cells derived from a Burkitt's lymphoma. (1967) (2)
- Quantitative comparison of direct and cold-target competition assay in monocyte- and complement-mediated lysis of sensitized erythrocytes. (1987) (2)
- Search for anti‐tumor response in a bone tumor patient with a long clinical history (1976) (2)
- Immunology and malignant disease. (1971) (2)
- Ligands of CR2 do not interfere with C3 fragment fixation or enhanced NK sensitivity of Raji cells treated with human serum. (1989) (2)
- Inhibitory effect of lymphocytes on DNA synthesis of target cells in vitro. (1966) (2)
- Studies on the expression of leukemia virus-controlled cell surface antigen and infectious virus release. (1973) (1)
- derived mononuclear cell cultures - EBV-infected cord blood Leukotriene B4 activates T cells that inhibit B-cell proliferation in (2013) (1)
- Decreased density in membrane localized macromolecules in cells enlarged after X-irradiation or polyploidization. (1980) (1)
- Human T-cell cultures with selective autotumor reactivity (2004) (1)
- GENERATION OF LYTIC POTENTIAL IN MIXED CULTURES AND ITS MODIFICATION BY IFN-α (1982) (1)
- Generation of cytotoxicity with various MHC class I restrictions against autologous LCL by stimulating the lymphocytes with autologous and/or allogeneic LCLs sharing HLA alleles with the responder. (1992) (1)
- Antigenic behavior of Moloney virus-induced lymphomas in mice. (1966) (1)
- Torbjörn Caspersson, 15 October 1910 - 7 December 1997. (2003) (1)
- Changes in the properties of the resident L virus in somatic cell hybrid lines. (1974) (1)
- Induction of K562 lysis in autologous LGL and dense T cell cocultures. (1985) (1)
- Immunological Control of EBV Infected B Cells (1983) (1)
- Sensitization of rat T cells to syngeneic tumor cultures by cocultivation in diffusion chambers. (1977) (1)
- Epstein-Barr virus (EBV) specific T and K cell cytotoxicity in vitro. (1975) (1)
- Immune interferon (IFN-gamma) production in autologous mixed cultures. (1983) (1)
- Purified mouse mammary tumor and lymphoid cells in immune assays (2004) (1)
- Genetic studies on natural resistance to Moloney lymphoma (YAC) isografts. I. Introduction of a non-H-2-linked resistance gene on strain A/Sn background (2004) (1)
- HOST RESPONSE TO EPSTEIN-BARR VIRUS INFECTED B CELLS (1985) (1)
- The nucleic acid content and the growth rate of mouse ascites tumor cells. (1951) (1)
- Epstein-Barr virus (EBV)-determined characteristics in lymphoid cells. (1975) (1)
- The scientist as a poet (2000) (1)
- Predominant rearrangements of the T cell receptor beta-chain gene in blood lymphocyte populations stimulated with autologous tumor cells suggest clonal T cell expansion in two of fourteen cases. (1991) (1)
- Resistance to growth of the moloney lymphoma YAC in semi‐syngeneic graft recipients (1988) (1)
- The immunology of host–tumour relationships (reply) (1985) (1)
- Tumor Antigens: Virus Induced (1971) (1)
- Cytotoxic factor produced by human blood lymphocytes of low density upon exposure to autologous B cells. (1986) (1)
- Lysis of Autologous Tumor Cells by Blood Lymphocytes In Vitro Requires MHC Class I Antigen Expression (1989) (1)
- Tumour-associated antigens. Potential application in research, tumour therapy and tumour prevention. (1972) (1)
- Application of isoelectric focusing for studies of major histocompatibility complex class I antigen expression on human carcinomas and sarcomas (2005) (1)
- HUMAN BLOOD LYMPHOCYTE SUBSETS CHARACTERIZED BY MONOCLONAL REAGENTS (1982) (1)
- Characteristics and in vitro growth influencing effects of the spleen cell population in a methylcholanthrene induced mouse sarcoma system. (1978) (1)
- Tumor surveillance: expression of the transporter associated with antigen processing (TAP-1) in ex-vivo human tumor samples and its elevation by in vitro treatment with IFN-gamma and TNF-alpha. (1998) (1)
- The fate of IgM and of anti IgM on antibody-coated Daudi cells (1976) (1)
- Regulation of tumor growth and antibody clone expression by antigen and anti‐idiotype antibody ligands with specificity for receptor‐binding sites (1979) (1)
- IFN-α-induced modulations of the events in human mixed lymphocyte cultures (1982) (1)
- Acquired immunodeficiency syndrome. (1983) (1)
- Characteristics of murine C‐type viruses. IV. The virus produced by ehrlich tumor cells and its hybrids with mouse L cells (1974) (1)
- The Lyt phenotype of the T cells in an antitumor adoptive transfer differs for "parent to F1" and "parent to parent" combinations. (1984) (1)
- Lymphocyte-mediated lysis of autologous and allogeneic B-cell lines in man. (1983) (1)
- Klein by Tumor-promoting Compounds Activation of Cytotoxic Activity of Human Blood Lymphocytes (2006) (0)
- Contribution of C3 Fragments to Lymphocyte Mediated Lysis of CR2 Carrying Cells (1988) (0)
- Interferon-gamma and tumor necrosis factor-alpha treatment of ex vivo human carcinoma cells potentiates their interaction with allogeneic lymphocytes. (1996) (0)
- The STAT5 transcription factor in B-cells of patients with chronic lymphocytic leukemia (2019) (0)
- Carcinoma into an “Ascites Tumor†(2016) (0)
- H-2 restriction of the cellular response in a methylcholanthrene sarcoma system studied with an F1 tumor and its H-2 loss variants. (1981) (0)
- Immune Response Directed Against Epstein-Barr Virus Carrier B Lymphocytes (1991) (0)
- [Intracellular endobiosis as a basic factor in acquired immunity in man (author's transl)]. (1976) (0)
- INCREASED ANTI K562 CYTOTOXICITY OF BLOOD MONONUCLEAR CELLS AFTER YELLOW FEVER VACCINATION, PROBABLY THE FUNCTION OF ACTIVATED T CELLS (1982) (0)
- Letter from George and Eva Klein to Joshua Lederberg (1959) (0)
- Contribution of the Microenvironment to the Pathogenesis of EBV-Positive Hodgkin and Nasal NK/T-cell Lymphomas (2008) (0)
- Natural Killer and Tumor Recognizing Lymphocyte Activity in Man (1979) (0)
- Genetic studies on natural resistance to moloney lymphoma (YAC) isografts (1985) (0)
- Effect of Interferon on Certain Cellular Immune Functions (1982) (0)
- 88 Leukotriene B4 Contributes to T Cell Mediated Inhibition of B Cell Growth in the EBV Infected Cord Blood Mononuclear Cell Cultures (2007) (0)
- Combined treatment with interferon (IFN)-gamma and tumor necrosis factor (TNF)-alpha up-regulates the expression of HLA class I determinants in Burkitt lymphoma lines. (1988) (0)
- The Tomizo Yoshida Prize. (1993) (0)
- Inflammatory cytokines and anti-microbial responses (PP-068) (2010) (0)
- CASE REPORT CELL SURFACE LOCALIZED IgM-KAPPA IMMUNOGLOBULIN REACTIVITY IN A CASE OF CHRONIC LYMPHOCYTIC LEUKAEMIA (1970) (0)
- Letter from Eva Klein to Joshua Lederberg (1958) (0)
- Immunity against Sarcoma Cells Humoral and Cellular Factors in Homograft and Isograft (2013) (0)
- Behavior of Solid and Ascites Sublines of Two Tumors in Tissue Culture (2006) (0)
- Epstein Barr Virus (EBV) infection of chronic lymphocytic leukemia cells (B-CLL): A model for the asymptomatic virus persistence in man (1997) (0)
- lymphoma-, and in NK-lymphoma derived cell lines protein-1 (LMP-1) in the absence of EBNA-2 in B-lymphocytes, in Burkitt IL-10 can induce the expression of EBV-encoded latent membrane (2013) (0)
- LYTIC EFFECT OF T-CELL CULTURES AGAINST TUMOR BIOPSY CELLS AND K562 (1982) (0)
- Cell-Mediated Immunity to EBV (1985) (0)
- Block EBV Infection In Vitro Selectively Target B Cells through CD21 and Released by EBV-Transformed B Cells Exosomes Containing Glycoprotein 350 (2010) (0)
- Reflections on human tumof immunology (1993) (0)
- OPPOSING TUMOROGENIC AND IMMUNOGENIC PROPERTIES OF THE IN VITRO AND THE IN VIVO SUBLINES OF MOLONEY INDUCED TUMOR (1979) (0)
- IFN-alpha-induced modulations of the events in human mixed lymphocyte cultures. (1982) (0)
- Immune Recognition of Tumor Cells Detected by Lymphocyte Mediated Cytotoxicity (1983) (0)
- Role of the Recognition of Virion Antigens in the T-Cell Mediated Inhibition of EBV-Induced B-Cell Transformation (1989) (0)
- Allo-restricted cytotoxicity recognizing EBV-determined antigens. Comments. (1987) (0)
- Immunity against Sarcoma Cells* (2006) (0)
- Cytotoxic susceptibility and defective MHC class I expression do not correlate with mutation of p53 in human carcinomas (2005) (0)
- Studies on the nucleic acid content of mouse ascites tumor cells under different experimental conditions. (1951) (0)
- into an ''Ascites Tumor'' The Transformation of a Solid Transplantable Mouse Carcinoma (2013) (0)
- THE IMPACT OF GENETICS AND GENETIC MONITORING ON ONCOLOGICAL STUDIES: Some aspects of leukemogenesis in the AKR strain (1983) (0)
- The Effect of TGFβ on the Growth of Burkitt Lymphoma and Lymphoblastoid Cell Lines (1990) (0)
- Role of H-2 antigens in the host response against transplanted methylcholanthrene-induced tumors (1983) (0)
- Interpretation and in vivo relevance of lymphocytotoxicity assays. (1981) (0)
- Generation of HLA-B55 restricted T lymphocyte mediated cytotoxicity against autologous LCL. (1994) (0)
- Enrichment and IFN-T Cell + CD57+ Associated with CD8 Inhibition of In Vitro EBV Infection That Is Cytomegalovirus-Seropositive Children Show (2013) (0)
- Blood-2011-Kis-165-74 Suppl (2013) (0)
- A N T I G E N I N H Y B R I D Cells* (2003) (0)
- Significance of the Cellular Antigens in Burkitt’s Lymphoma (1972) (0)
- Activation of B Lymphocytes by Zymosan-Bound C3 Fragments (1988) (0)
- Compatibility variants of the yac (moloney) lymphoma. (1981) (0)
- Perspectivesin CancerResearch Conditioned Tumorigenicity of Activated Oncogenes 1 (2006) (0)
- Epstein-Barr Virus (EBV)-Determined Characteristics in Lymphoid Cells1 (1976) (0)
- Growth of mammary tumor cells: differences between tumor associated and other lymphoid cells. Abstr. (1980) (0)
- INFLUENCE OF ANTIBODIES ON LYMPHOCYTE CYTOTOXICITY (2003) (0)
- Expression of interleukin-2 receptor on blood lymphocytes stimulated with allogeneic lymphocytes or autologous tumor cells (1990) (0)
- Epstein-Barr virus associated lymphomas (2009) (0)
- Roles of EBV in Haemopoetic Malignancies (2005) (0)
- Cytotoxicity of autosensitized lymphocytes restricted to the H-2K end of targets (1975) (0)
- [Studies on tumour--associated immunoglobulins in human cancer]. (1977) (0)
- Surface marker characterization of EBV-carrying cells in blood of healthy seropositive individuals. (1988) (0)
- The Impact of the Presence of EBV on the Interaction of B Cell Lines with T Lymphocytes (1988) (0)
- EBV infection of B‐CLL cells in vitro potentiates their allostimulatory capacity if accompanied by acquisition of the activated phenotype (1995) (0)
- Letter from George and Eva Klein to Joshua and Esther Lederberg (1960) (0)
- Activation of the cytotoxic effectors by autologous ex-vivo solid human tumors (1991) (0)
- Reflections on human tumor immunology. (1993) (0)
- Torbjörn Caspersson: some personal perspectives. (1984) (0)
- EFFECT OF IFN AND PHA ON THE CYTOTOXIC ACTIVITY OF BLOOD LYMPHOCYTE SUBSETS (1982) (0)
- The use of histocompatibility genes as markers in the study of genetic variation in heterozygous tumors. (1960) (0)
- [The third component of complement (C3) and its contribution to the immune response]. (1987) (0)
- I. DEPENDENCE OF CELL MEMBRANE IMMUNOFLUORESCENCE ON PRESENCE OF EB Vmus (2003) (0)
- Human T-cell leukemia virus-associated nuclear antigen (HTLV-NA). (1986) (0)
- Enhancement of Fc epsilon RII/CD23 expression on U937 cells with opsonized zymosan: the requirement of a Fc gamma RI/CD64 mediated signal associated phagocytosis. (1993) (0)
- Effect of stilbamidine on ascites tumor of mice (1950) (0)
- Interpretation of lymphocytotoxicity assays and the demonstration of auto-tumor reactive lymphocytes in patients: central issues of present day tumor immunology. (1983) (0)
- 149 The role of the microenvironment in EBV associated lymphoid malignancies (2009) (0)
This paper list is powered by the following services:
Other Resources About Eva Klein
What Schools Are Affiliated With Eva Klein?
Eva Klein is affiliated with the following schools:
